A new test for detecting Lyme disease directly from blood samples.
Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections.
This study is working on a new, super-sensitive test called RaPID/LD that can quickly and accurately find the Lyme disease bacteria in blood samples, helping people get the right treatment sooner and avoid serious health issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Helixbind, INC. NIH-funded |
| Lab location | 1 site (Boxborough, UNITED STATES) |
| Project ID | NIH-11064861 on NIH RePORTER |
What this research studies
This research focuses on developing an ultra-sensitive test called RaPID/LD for the direct detection of Borrelia, the bacteria that causes Lyme disease, from blood samples. Currently, diagnosing early Lyme disease is challenging due to the limitations of existing laboratory tests, which often fail to identify active infections. The RaPID/LD test aims to provide a more accurate and timely diagnosis, potentially preventing severe complications associated with delayed treatment. By utilizing advanced molecular diagnostic techniques, this test could significantly improve the detection of Lyme disease in its early stages.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are suspected of having Lyme disease, particularly those presenting with early symptoms.
Not a fit: Patients who have already been diagnosed with Lyme disease and are undergoing treatment may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of Lyme disease, improving treatment outcomes for patients.
How similar studies have performed: While there have been advancements in molecular diagnostics for various infections, the specific approach of ultra-sensitive detection of Borrelia from blood is relatively novel and has not been widely tested.
Where this research is happening
Boxborough, UNITED STATES
- Helixbind, INC. — Boxborough, United States (Active)
Researchers
- Principal investigator: Singer, Alon — Helixbind, INC.
- Study coordinator: Singer, Alon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.